Novavax (NASDAQ:NVAX) Upgraded at Wall Street Zen

Novavax (NASDAQ:NVAX) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.

NVAX has been the subject of a number of other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Novavax in a research note on Tuesday, October 27th. Citigroup restated a “sell” rating and issued a $8.00 price target (up from $7.00) on shares of Novavax in a research note on Thursday, October 15th. Weiss Ratings reissued a “sell (d)” rating on shares of Novavax in a report on Monday. B. Riley Financial reiterated a “buy” rating and issued a $16.00 target price (down from $18.00) on shares of Novavax in a report on Friday. Finally, Zacks Research lowered shares of Novavax from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $12.33.

Novavax Stock Up 10.2%

NASDAQ NVAX opened at $10.78 on Friday. Novavax has a 52 week low of $6.20 and a 52 week high of $13.39. The company has a fifty day moving average of $10.56 and a two-hundred day moving average of $9.35. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -23.43 and a beta of 2.65.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.16. The firm had revenue of $68.30 million during the quarter, compared to analysts’ expectations of $50.42 million. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. Novavax’s revenue was down 3.0% compared to the same quarter last year. During the same period last year, the business earned ($1.25) earnings per share. Equities research analysts anticipate that Novavax will post -0.38 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVAX. Bank of New York Mellon Corp acquired a new stake in Novavax during the second quarter worth about $8,004,000. Edgestream Partners L.P. bought a new position in shares of Novavax during the 1st quarter worth approximately $4,234,000. Renaissance Technologies LLC acquired a new stake in shares of Novavax in the 1st quarter valued at approximately $4,049,000. Squarepoint Ops LLC acquired a new stake in shares of Novavax in the second quarter valued at about $1,258,000. Finally, First Trust Advisors LP increased its position in shares of Novavax by 37.7% during the first quarter. First Trust Advisors LP now owns 409,328 shares of the biopharmaceutical company’s stock valued at $3,332,000 after buying an additional 112,009 shares during the period. Institutional investors own 53.04% of the company’s stock.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a Q3 loss of $0.19 per share, narrower than analysts’ expected $0.35 loss, while revenue of $68.3 million topped estimates of about $50.4 million. The loss also improved from $0.62 per share a year earlier. Article: Novavax Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: The company raised its 2026 revenue outlook to $385 million–$415 million, or $400 million at the midpoint—about $145 million higher than its prior framework. A $125 million milestone from Sanofi, earned after a Phase 3 trial launch, accounts for much of the increase. Novavax also reduced operating expenses and said its cash runway extends into 2029. Article: Novavax boosts 2026 revenue forecast as licensing deals pay off
• Neutral Sentiment: B. Riley reaffirmed its Buy rating, though it lowered its price target to $16 from $18. The reduced target tempers the otherwise positive analyst stance. Article: B. Riley stock recommendations
• Negative Sentiment: Investors may be focused on Novavax pushing its profitability target out to 2029. Q3 revenue was still down 3% year over year, and the higher 2026 outlook depends substantially on the Sanofi milestone, raising questions about the durability of revenue growth. Article: Novavax pushes profitability target to 2029, shares dip

About Novavax

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.